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Abstract
Background: It has been hypothesized that early host-responses during TB treatment may paradoxically promote survival of
persistent bacteria. We therefore evaluated whether adjunctive inhibition of tumor necrosis factor alpha (TNF-a)–a key
cytokine in host responses against TB–could hasten bacterial clearance in a mouse strain that develops necrotic lesions in
response to Mycobacterium tuberculosis infection.
Methodology/Principal Findings: Six weeks after an aerosol infection, C3HeB/FeJ mice received standard TB treatment with
or without adjunctive TNF inhibition (etanercept for the initial six weeks). Functional TNF-a levels and lung pathology were
found to be reduced in the mice receiving etanercept. Compared to standard TB treatment, the addition of etanercept
resulted in a significantly lower pulmonary bacterial burden, corresponding to the phase when a significant proportion of
bacteria are multiplying slowly (p,0.0233). Finally, only 10.5% of mice receiving adjunctive etanercept versus 27.8%
receiving standard TB treatment alone relapsed.
Conclusion: This study provides proof-of-principle that modulation of TNF-a activity can hasten bacterial clearance during
standard multi-drug TB treatment. Oral agents that modulate TNF-a should therefore be considered as adjunct therapies for
shortening TB treatments. However, due to concerns of reactivation disease, additional studies need to be performed
before TNF-a inhibitors are used for TB treatment in humans.
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Introduction
Recognizing that tuberculosis (TB) is still the leading cause of
human death from a curable disease, the international health
community has set an ambitious target to eliminate TB by 2050.
Using mathematical modeling Dye et al have shown that the 2050
target cannot be achieved with current tools and requires
a combination of new diagnostics, shorter TB drug regimens
and new vaccines that can detect and treat both latent infection
and active disease [1].
It has been hypothesized that early host-responses – in-
flammation, necrosis and subsequent hypoxia – during TB
treatments may paradoxically promote survival of persistent
bacteria [2]. In fact, adjunct corticosteroid use for the initial 6-
weeks is helpful in certain forms of TB (meningitis, pleural TB)
[3], though these data are less clear for pulmonary TB. Tumor
necrosis factor alpha (TNF-a) is a cytokine that plays a central
role in the host responses against TB, including formation of
granulomas and containment of disease [4,5,6]. Although TNF-
a inhibition leads to reactivation disease [7,8], it has been
hypothesized that adjunctive use of TNF-a inhibitors during TB
treatments may paradoxically be beneficial [9]. This is plausible
as TNF-a levels increase shortly after initiation of TB treatment
[10], causing tissue destruction, creating a microenvironment
which could favor bacterial survival. This hypothesis is
supported by case reports and small series that demonstrate
that adjunctive use of TNF-a inhibitors with TB treatments is
beneficial [11,12,13,14].
Pre-clinical evaluation of multi-drug TB treatments is well
established in the mouse model of TB. However, necrosis and
hypoxia, key pathological features of human TB lesions, postulated
to favor survival of persistent bacteria, are lacking in conventional
mouse strains. We therefore utilized C3HeB/FeJ mice, which
develop well-organized [15] and hypoxic TB granulomas with
central caseous necrosis [16], and evaluated whether adjunctive
TNF-a inhibition combined with standard TB treatment could
hasten bacterial clearance.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39680Methods
Ethics Statement
All animal procedures have been approved by the ethics
committee of Johns Hopkins University.
Animal Infections
Six-to-eight week old female C3HeB/FeJ (Jackson Laboratory)
mice were aerosol infected with frozen titrated bacterial stocks of
Mycobacterium tuberculosis H37Rv, using the Middlebrook Inhalation
Exposure System (Glas-Col). Mice were sacrificed 1 day after
infection and at 2, 4, 8, 10 and 12 weeks after starting TB
treatments. Lungs and spleens were removed aseptically, homog-
enized and plated on Middlebrook 7H11 agar plates (Fisher, USA)
to determine colony-forming unit (CFU). A minimum of 4 mice
were used per group and for each time-point.
Multi-drug TB Treatments
Treatment began 6 weeks after a low-dose aerosol infection.
Mice were administered the standard TB regimen with Rifampin
(10 mg/kg), Isoniazid (25 mg/kg) and Pyrazinamide (150 mg/kg)
by gavage, 5 days per week for a total of 12 weeks. Pyrazinamide
was administered only for the first 8 weeks, as is standard for TB
treatment in humans [3]. Animals were injected intraperitoneally,
twice weekly, with etanercept (Amgen, USA) (15 mg/kg) [17].
Etanercept - a soluble TNF receptor fusion molecule (sTNFR) was
chosen for these experiments since the risk of reactivation is lower
in patients receiving etanercept than in those receiving TNF
antibodies, suggesting that sTNFR may be safer [18,19].
Relapse
Additional cohorts of mice were held for 12 weeks after
cessation of treatment to assess for stable, relapse free cure. At this
time, lungs and spleens were removed aseptically, homogenized
and plated on Middlebrook 7H11 agar plates. The complete
homogenate was plated across several plates, for each organ.
Histopathology
To assess pulmonary inflammation and injury, entire mouse
lungs were fixed by immersion in 10% (vol/vol) formalin, and
following paraffin embedding, 4-mm longitudinal sections were
cut, stained with hematoxylin and eosin. Images shown are
representative of section obtained from 4 animals per group and
for each time-point.
Morphometric Analysis of Lung Tissue
To further evaluate the differences noted in lung pathology,
morphometric analyses were performed on lung tissues obtained
from the standard treatment (RHZ alone) and adjunctive
etanercept (RHZ plus etanercept) arms using Image J software
(NIH, USA). A minimum of three fields of view, obtained from
four animals per group, for each time-point were used (12 fields
per group for each time-point). Lung involvement was calculated
as the percent of lung tissue occupied by lesions.
ELISA
Cytokine concentrations were measured by sandwich ELISA in
a 96 well plate pre-coated with capture antibodies (Abcam, USA).
The plates were washed with Wash Buffer [PBS-Tween 20 (0.05%
v/v)] and blocked using 300 ml of 10% (w/v) milk powder for 2
hours at room temperature before the addition of recombinant
standards and samples and a 2 hour incubation at room
temperature. Following incubation, plates were washed and
detection antibody added for 1 hour at room temperature.
Following this, streptavidin-HRP was added followed by 3,39,5,59 -
tetramethylbenzidine (TMB) substrate and color allowed to
develop in the dark. Plates were then read on a spectrophotometer
at an optical density of 450 nm.
TNF-a Activity
TNF-a activity was measured using the WEHI assay [20]. Lung
homogenates were filter sterilized through a 0.22 mm filter before
being diluted two-fold in sterile PBS and added, in triplicate, to
a 96-well containing 2610
5 WEHI13-VAR cells (ATCC, USA).
At the same time, a standard curve was prepared using 2-fold
dilutions of recombinant murine TNF-a (Sigma-Aldrich, USA),
ranging from 0 to 200 units per well. Following a 24 hour
incubation with the lung homogenate or recombinant TNF-a at
37uC and 5% CO2, 100 mg of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide was added to each well and in-
cubated at 37uC, 5% CO2 for an additional 4 hours. Following the
addition of DMSO, plates were read at 595 nm and activity
calculated as a function of the standard curve. For neutralization
assays samples were incubated for 60 minutes at 37uC with ten-
fold dilutions of a goat anti-mouse TNF-a antibody (Abcam,
USA). Triplicate, filter sterilized lung tissue homogenates were also
tested for TNF-a using ELISA (as described above). Data was
normalized to the total protein concentration of the tissue samples.
Cytokine Analysis
Cytokine concentrations were determined by Bio-Plex Pro
Assay (Bio-Rad, USA) according to the manufacturer’s instruc-
tions or ELISA (as described above). Four mice were used per
group and for each time-point. Splenocytes were isolated by
disaggregation of whole mouse spleens and seeded at a concen-
tration of 1610
6 cells/ml in a total volume of 200 ml. After
72 h of incubation in the presence of heat-inactivated M.
tuberculosis (H37Rv), culture supernatants were sampled for select
cytokines. Dye labeled cytokine-specific antibodies were mixed
with sample, washed and targeted with a biotinylated detection
antibody. The resultant antibody sandwich was visualized using
streptavidin-PE. Acquisition and analyses was then performed
using the Luminex system. Results are presented as pg/ml of
supernatant.
Statistical Analysis
Statistical comparison between groups was performed using two
tail Student’s t test in Prism 4 version 4.01 (GraphPad software,
San Diego, CA). Data are presented on a logarithmic scale as
mean 6 standard deviation for CFU counts, except where stated.
Results
Adjunctive Etanercept Reduced Local TNF-a Activity in
the Lung Tissues
Soluble TNF-a inhibitor, etanercept, was administered as an
adjunct to standard TB treatment (RHZ) and bacterial burden
measured in the lungs of treated animals. Etanercept, a soluble
TNF-a receptor fusion molecule (sTNFR), works by binding with
the endogenous TNF-a, which subsequently is unable to interact
with its native receptor. To ensure that etanercept reduced local
TNF-a activity in the lung tissues, functional TNF-a activity and
levels were measured by the WEHI assay [20] and ELISA
respectively (Figure 1). As expected, compared to untreated mice,
the TNF-a activity increased in the TB treatment arm. This
increased TNF-a activity, was significantly reduced by the
administration of adjunctive etanercept (p#0.03) (Figure 1A, B).
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WEHI assay was indeed due to TNF-a and not other endogenous
factors present in the sample, lung homogenates from both the
standard treatment (RHZ alone) and adjunctive etanercept (RHZ
plus etanercept) arms were pre-incubated with increasing con-
centrations of a neutralizing anti-murine TNF-a antibody and
tested using the WEHI assay (Figure 1C). Lung homogenates from
the adjunctive etanercept arm had consistently lower TNF-
a activity, which remained unaffected by pre-incubation with
the neutralizing antibody. However, TNF-a activity in the lung
homogenates from the standard treatment arm decreased in
a dose-dependent manner with increasing concentrations of the
neutralizing antibody, with activities at 100 or 10 fold dilutions
reaching levels observed in the adjunctive etanercept arm
(p.0.098).
Adjunctive Etanercept Increases Bacterial Clearance
During the Continuation Phase of TB Treatment
The addition of etanercept did not alter bacterial killing
significantly during the initial phase of TB treatment, when the
majority of bacteria are replicating actively, and effectively cleared
by antimicrobial treatment alone (Figure 2A). However, at later
time-points (8, 10 weeks of treatment), corresponding to the phase
when a significant proportion of bacteria are multiplying slowly
(persisters), the addition of etanercept resulted in a significantly
lower bacterial burden (p =0.0233; p =0.0174 at 8 and 10 weeks
respectively) (Figure 2B, C). Both the groups receiving standard
TB treatment or adjunctive etanercept were culture negative after
12 weeks of treatment.
Additional cohorts of mice were held for 12 weeks after
cessation of treatment to assess for relapse. Only 10.5% (2/19) of
mice receiving adjunctive etanercept versus 27.8% (5/18) re-
ceiving standard TB treatment alone relapsed.
Adjunctive Etanercept Reduces TB-associated Pathology
Previous work using TNF-a inhibition, in mice demonstrated
a role for TNF-a in granuloma formation and integrity. Mice
receiving TNF-a inhibitors were reported to form lesions which
were more loosely packed and lacking epithelioid cells [4]. To
determine the effect of TNF-a inhibition on lung pathology,
hematoxylin and eosin stains were assessed throughout the study.
As shown in Figure 3, pulmonary lesions in animals receiving
adjunctive etanercept (RHZ plus etanercept, Panel B) appeared to
resolve earlier than those receiving standard treatment (RHZ
alone, Panel A). Morphometric analysis also demonstrated re-
duced lung involvement in mice treated with adjunctive etanercept
(RHZ plus etanercept) versus standard treatment (RHZ alone)
(Figure 3C). These differences were statistically significant at 4
weeks (p=0.0139).
Immune Responses During TB Treatments
Splenic recall assays were performed to monitor the immune
responses during TB treatment with and without adjunctive
etanercept. Infected but untreated mice and mice treated with
etanercept alone were used as controls. High levels of IL-2,
a cytokine required for development and differentiation of
CD8+ memory T-cells, and CCL4, a chemokine produced in
large quantities by CD8+ T-cells, were noted in mice receiving
standard TB treatment with or without or adjunctive etanercept
(Figure 4). Conversely, higher levels of anti-inflammatory
cytokine IL-10 were only noted in the untreated mice. IFN-c
levels were also measured by ELISA. Similar to IL-2, IFN-c
levels increased progressively during TB treatment with RHZ
alone or with adjunctive etanercept. However, neither untreated
or etanercept alone treated groups produced appreciable levels
of IFN-c. Overall, this is indicative of a transition, from
a regulatory to an effector phenotype, following the onset of
treatment.
Discussion
New and shorter TB regimens are needed to improve the
treatment of TB and to support global control efforts. However,
current TB treatments largely target actively replicating
bacteria. Killing of the slow-replicating, persistent microbes
requires protracted treatment with multiple drugs. Human
studies demonstrate that patients receiving TNF-a inhibitors
for chronic inflammatory diseases (rheumatoid arthritis, Crohn
Figure 1. TNF-a activity in the lungs of treated mice. TNF-a activity was measured in lung homogenates obtained from Mycobacterium
tuberculosis infected C3HeB/FeJ mice by WEHI assay (A) and ELISA (B). Levels for mice receiving no treatment (Untreated), standard TB treatment
(RHZ) or with adjunctive etanercept (RHZ + Etanercept) were measured 7 days after the start of treatment. TNF-a activity increased with TB treatment
and was abrogated by the administration of adjunctive etanercept. Moreover, to ensure that the TNF-a activity measured using the WEHI assay was
indeed due to TNF-a and not other endogenous factors, lung homogenates from both the standard treatment (RHZ alone) and adjunctive etanercept
(RHZ plus etanercept) arms were pre-incubated with increasing concentrations of a murine anti-TNF-a antibody and tested using the WEHI assay (C).
Lung homogenates from the adjunctive etanercept arm (open bars) had consistently lower TNF-a activity which remained unaffected by pre-
incubation with the neutralizing antibody. However, TNF-a activity in the lung homogenates from the standard treatment arm (filled bars) decreased
in a dose-dependent manner with increasing concentrations of the neutralizing antibody, with activities at 100 or 10 fold dilutions reaching levels
observed in the adjunctive etanercept arm. Analyses were performed on two-fold diluted lung homogenate from four mice per group. Data is
normalized to the total protein concentration of the tissue samples and is presented as mean activity (U/ml/g) (6SD) in panels A, C and mean level
(pg/ml) (6SD) in panel B.
doi:10.1371/journal.pone.0039680.g001
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TNF-a inhibition in combination with effective TB treatment
may therefore enhance the clearance of persisters, and could
therefore potentially shorten TB treatments. Amongst all the
animal models, multi-drug TB chemotherapy is most well
established in the mouse. However, necrosis and hypoxia, key
pathological features of human TB lesions, thought to favor
survival of persistent bacteria, are lacking in conventional mouse
strains. We therefore utilized C3HeB/FeJ mice, which develop
well-organized and hypoxic TB granulomas, with central
caseous necrosis [16], and evaluated whether adjunctive TNF-
a inhibition could hasten bacterial clearance. We studied the
time-specific inhibition of TNF-a, after granuloma formation
had already occurred, a situation analogous to what would be
seen with human patients presenting with active TB. Our data
suggests that time-specific inhibition of TNF-a in combination
with effective TB treatment, resulted in reduced necrosis and
faster resolution of TB lesions. This was associated with
improved bacterial killing during the continuation phase of
treatment. The availability of mouse specific reagents also
allowed us to evaluate the immune responses during TB
treatments in this model. Since etanercept is a foreign antigen
for mice, antibodies against the molecule are likely to appear
following repeated administration of the protein. Lories RJ et al
have shown that even though high antibody titers may be
present in the serum of etanercept-treated mice, the presence of
antibodies does not block the effect of etanercept [21]. To
ensure that etanercept reduced local TNF-a activity in the lung
tissues, we measured functional TNF-a activity by the WEHI
assay [20] and total TNF-a protein by ELISA. As demonstrated
previously in humans [10], TNF-a activity increased shortly
after initiation of standard multi-drug TB treatment in our
model. This increase in TNF-a activity was abrogated by the
administration of adjunctive etanercept. Finally, to ensure that
the TNF-a activity measured using the WEHI assay was indeed
due to TNF-a and not other endogenous factors present in the
Figure 2. Bacterial burden in the lungs of mice. Six weeks after an aerosol infection with Mycobacterium tuberculosis, C3HeB/FeJ mice were split
among four treatment groups: Untreated (no treatment), standard TB treatment (RHZ), etanercept alone and standard TB treatment with adjunctive
etanercept (RHZ + Etanercept). The number of viable bacteria in the lungs were estimated by determining colony-forming units (CFU). Results are
shown for the duration of study (panel A) and also as individual dot plots for 8 (panel B) and 10 (panel C) weeks after starting TB treatment.
Compared to standard TB treatment, the addition of etanercept resulted in a significantly lower pulmonary bacterial burden, corresponding to the
phase when a significant proportion of bacteria are multiplying slowly (panels B, C). Results are presented as mean (6SD) CFU in the lungs, detected
from a minimum of four mice at each time point and for each group. CFU are presented on a logarithmic scale (log10) in panel A and on a linear scale
for panels B and C and represent the same data.
doi:10.1371/journal.pone.0039680.g002
TNF Inhibition Improves TB Treatment
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39680sample, lung homogenates from both the standard treatment
(RHZ alone) and adjunctive etanercept (RHZ plus etanercept)
arms were pre-incubated with increasing concentrations of
a neutralizing anti-murine TNF-a antibody and tested using
the WEHI assay. These assays proved that the TNF-a bioactivity
measured using the WEHI cells was indeed related to TNF-
a and not to other cytotoxic factors. Moreover, splenic recall
assays suggested that a predominant regulatory phenotype
existed before the administration of TB treatments. However,
standard TB treatment (with and without adjunctive etanercept)
induced a switch to an IFN-c+, IL-2+, CCL4+ effector
phenotype indicative of strong Th1and CD8+ response. This
is in keeping with human data by Caccamo et al. which
demonstrated an increased CD8+ T-cell population in the blood
of actively infected individuals following TB treatments [22].
Also, these data indicate that adjunctive use of etanercept with
TB treatments did not prevent mice from generating a cytotoxic
T-cell response. Though more generalized immune modulation
in combination with antimicrobial therapy may also effect better
bacterial killing [23], use of specific immunomodulators could
reduce the untoward side effects. It should be noted that recent
studies in mice [24,25] and rabbits [26], using phosphodiester-
ase inhibitors, which modulate TNF-a, has also demonstrated
improved pathology, and increased bacterial killing when
combined with INH monotherapy. Finally, it should be noted
that we utilized etanercept (sTNFR) in the current study due to
its lower risks in causing reactivation disease than with TNF
antibodies [18,19]. However, given the proposed mechanism of
action (effects on granuloma integrity), it is possible that greater
therapeutic benefit could be achieved using TNF antibodies.
In summary, the current study provides proof-of-principle that
modulation of TNF-a activity can hasten bacterial clearance when
combined with standard multi-drug TB treatment. Moreover, oral
TNF-a inhibitors such as tofacitinib (CP-690550) and fostamatinib
are currently being evaluated for treating chronic inflammatory
diseases [27,28]. As oral drugs (versus currently available inject-
able TNF-a inhibitors), these agents are better suited (lower costs
and ease of administration) for combination with TB programs in
resource limited settings. Oral agents that modulate TNF-a should
therefore be considered as adjunct therapies that could shorten TB
treatments and will be the focus of our future pre-clinical studies.
However, due to the multitude of human studies demonstrating
that patients receiving TNF-a inhibitors for chronic inflammatory
diseases (rheumatoid arthritis, Crohn disease) can develop
reactivation TB disease [7,8,18], we acknowledge the significant
risks of such treatment. Therefore, additional studies need to be
Figure 3. Adjunctive etanercept reduces TB-associated pathology. Hematoxylin and eosin staining (20x and 200x – inset) was performed on
lung tissues. Images shown are representative of sections obtained from 4 animals per group. Each time-point is shown in weeks on the individual
images. Lung pathology in animals receiving adjunctive etanercept (RHZ plus etanercept) (panel B) appeared to resolve earlier than those receiving
standard treatment (RHZ alone) (panel A). Morphometric analysis confirmed these findings and demonstrated reduced lung involvement in mice
treated with adjunctive etanercept (RHZ plus etanercept; blue x) versus standard treatment (RHZ alone; red %) (panel C). Results are represented as
percentage lung involvement, calculated using ImageJ software.
doi:10.1371/journal.pone.0039680.g003
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TB treatment in humans.
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